Article Text

other Versions

PDF
Lipoatrophy with insulin analogues in type I diabetes
  1. Amir Babiker,
  2. Vipan Datta
  1. Jenny Lind Children's Department, Norfolk and Norwich University Hospital, Norwich, UK
  1. Correspondence to Dr Vipan Datta, Jenny Lind Children's Department, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK; vipan.datta{at}nnuh.nhs.uk

Abstract

Lipoatrophy is a rare complication of treatment with insulin analogues. It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). To our knowledge, this is one of the first reports of lipoatrophy with Aspart, biphasic Aspart and Detemir insulin analogues (Novo Nordisk, Bagsvaerd, Denmark). We report the cases of four children with type I diabetes who were commenced on NovoMix 30 or NovoRapid/Levemir insulin injections. They developed lipoatrophy at the injection sites after 2–3 years of treatment. In two of our patients, lipoatrophy resolved when the injection sites were changed, suggesting that local factors could be the cause of lipoatrophy. However, lipoatrophy developed at the new sites in the other two patients, requiring a change of insulin preparation. Regular examination of the injection sites facilitated early detection of lipoatrophy in our patients. Lipoatrophy completely resolved over 1–2 years in all patients with no recurrence after 3–4 years of follow-up.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Parental consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.